Stock Ratings / Health Care / IMRX / dividends

ABEO (39) AMRN (43) QTTB (61) BCYC (24) ⌘ Pro Terminal →

Immuneering Corporation (Class A) (IMRX) Dividend Safety Gauge & 10-Year DRIP Compounder

$4.02 +0.75% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $4.02

Immuneering Corporation (Class A) (IMRX) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $260.1M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on IMRX Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is IMRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-01, Immuneering Corporation (Class A) (NASDAQ: IMRX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $4.02 (+0.75% 1D, market cap $260.1M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, IMRX ranks #481 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does IMRX compare to ABEO and AMRN in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), IMRX carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ABEO (Abeona Therapeutics Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $260.8M) and AMRN (Amarin Corporation plc) posts a D- grade (43/100 RQD, P/E N/A, ROIC -12.2%, cap $262.8M). Among the 5-stock peer group, QTTB leads on earnings multiple (8.9x) while QTTB leads on capital efficiency (85.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for IMRX?

▼

Per IMRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001790340), Immuneering Corporation (Class A) generated $0 in revenue, -$56.0M in net income, and -$45.5M in free cash flow against $232.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $4.02 (-0.05%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.3% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for IMRX)Realized 20D OHLCV Swing Band: ±12%

Deterministic 5-Pillar Attribution (45/100 Composite)

🔍 WHY IMRX SCORES 45/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+12/20 pts (27% of score)

20D Institutional Volume Accumulation (±12% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+12/20 pts (27% of score)

FRED Regime × Technicals: 13% of 52W Range • RSI-14 at 43.1 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$3.94-8.9% Next Q

Q2 (-2Q)

Grade D$3.59+3.9% Next Q

Q3 (-1Q)

Grade D$3.73+7.8% Next Q

Current

Grade D$4.02-6.3% Hist 90D α

Trajectory: E (37) → D (45)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a IMRX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While IMRX currently carries a cautious 45/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.28) and Max Pain ($4.22) forces dealer call-delta covering toward $8.90.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $IMRX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “IMRX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 45%NO 55%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

0.6% Total Yield

0% Cash ($0.00/yr) + 0.6% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $17,081

Est. Year-10 Shareholder Yield: $102/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.6K

Yr 1

$11.1K

Yr 2

$11.7K

Yr 3

$12.4K

Yr 4

$13.1K

Yr 5

$13.8K

Yr 6

$14.5K

Yr 7

$15.3K

Yr 8

$16.2K

Yr 9

$17.1K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring IMRX)

✓Walkthrough of IMRX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

IMRX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -23.28%⚡ TESTING RESISTANCE

2026-10-30O $4.01H $4.07L $3.72C $4.02VOL 1.14M

RES: $4.11SUP: $3.25SMA50: $4.28SMA200: $4.81

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

IMRX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 IMRX Butterfly Map → + Track IMRX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on IMRX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for IMRX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for IMRX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IMRX)

Health Care Rank #481 of 1016 ⚔️ ABEO vs IMRX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (IMRX vs. ABEO, AMRN, QTTB, BCYC)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Immuneering Corporation (Class A) (IMRX) ranks #481 by composite RQD confidence (45/100, grade D) and #542 by equity capitalization ($260.1M). Within this direct 5-issuer industry benchmark cohort, QTTB leads on earnings valuation at 8.9x trailing P/E, while QTTB leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. QTTB currently holds the highest overall quantitative score in the immediate peer group at 61/100 (C-) compared with IMRX at 45/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
IMRX ACTIVE Immuneering Corporation (Class A)	D	45/100	—	—	-35.0%	+0.75%	$260.1M	Benchmark Subject
ABEO Abeona Therapeutics Inc.	D-	39/100	—	73.7%	-35.0%	+0.22%	$260.8M	/abeo-vs-imrx →
AMRN Amarin Corporation plc	D-	43/100	—	56.6%	-12.2%	-0.08%	$262.8M	/amrn-vs-imrx →
QTTB Q32 Bio Inc.	C-	61/100	8.9x	—	85.0%	-2.10%	$264.1M	/qttb-vs-imrx →
BCYC Bicycle Therapeutics plc	E	24/100	—	—	-35.0%	-1.55%	$267.4M	/bcyc-vs-imrx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001790340

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Immuneering Corporation (Class A) (IMRX) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$56.0M, operating cash flow of -$45.3M, and free cash flow of -$45.5M (+17.4% YoY). On the balance sheet, IMRX closed FY2025 with $232.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$56.0M	-$45.3M	-$45.5M	$232.0M	—
FY2024 (FY)	2024-12-31	$0	-$61.0M	-$55.0M	-$55.1M	$52.7M	—
FY2023 (FY)	2023-12-31	$0	-$53.5M	-$49.0M	-$49.0M	—	—

3. IMRX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is IMRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does IMRX compare to ABEO and AMRN in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for IMRX?

Where is IMRX trading relative to its 50-day, 200-day, and 52-week technical levels?

IMRX last traded at $4.02 (+0.75% on volume of 777,079 shares), positioning the stock -6.07% below its 50-day simple moving average ($4.28) and -16.42% below its 200-day simple moving average ($4.81). Across its 52-week range of $3.38 to $8.48, IMRX sits at the 12.5% percentile with a 14-day RSI of 43.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.0% ($3.54 to $4.50).

IMRX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does IMRX pay a dividend and is it safe?

Immuneering Corporation (Class A) (IMRX) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: IMRX RQD Cockpit IMRX 12M Forecast IMRX Earnings & Move IMRX Dividends & DRIP IMRX Insiders & 13F IMRX Whale Options IMRX Profit Sankey IMRX News & Why